SL-279252 is the first Agonist Redirected Checkpoint molecule to
enter clinical development from the Shattuck pipeline.
AUSTIN, Texas–(BUSINESS WIRE)–Shattuck Labs, Inc. (“Shattuck”), a biopharmaceutical company, announced
today that patients are being treated in its Phase 1 dose escalation and
expansion clinical trial of its molecule SL-279252 (PD1/OX40L), a
bi-functional fusion protein (https://clinicaltrials.gov/ct2/show/NCT03894618).
Sarah Cannon Research Institute in Nashville, Tennessee and MD Anderson
Cancer Center in Houston, Texas are the first enrolling sites in this
multi-center, global trial. This first-in-human study is designed to
evaluate the safety, tolerability, pharmacokinetics, pharmacodynamic,
and anti-tumor activity of SL-279252 in patients with advanced solid
tumors or lymphomas. Takeda Pharmaceutical Company Limited currently
holds an exclusive option to enter into a license to develop and
commercialize SL-279252. Further information about this trial can be
found on clinicaltrials.gov.
“We are excited to have initiated clinical studies for SL-279252. While
some patients with cancer enjoy long-term benefit from antibody-based
PD-1 blockade, a majority of patients unfortunately do not,” explained
Lini Pandite, M.D., Chief Medical Officer of Shattuck. “Pre-clinical
studies demonstrate that SL-279252 binds simultaneously and with high
affinity to PD-L1 and OX40, and stimulates anti-tumor T cell activity.
Pre-clinical studies further demonstrate improved pharmacologic and
anti-tumor activity compared to antibody-based PD-1 blockade, either
alone or in combination with antibody-based OX40 stimulation. We look
forward to learning more about SL-279252 in the clinic and expect to
gain insight into whether it can improve upon antibody-based PD-1
blockade as a standard of care in multiple tumor types.”
SL-279252 is a novel therapeutic derived from Shattuck’s proprietary
Agonist Redirected Checkpoint (ARC™) platform and its first molecule to
begin clinical trials. The dual-sided nature of SL-279252 is designed to
simultaneously block the PD-L1 inhibitory signal and stimulate OX40
signaling. Preclinical studies have demonstrated that SL-279252 potently
stimulates anti-tumor T cell activity.
“Shattuck’s ARC platform technology combines checkpoint blockade with
immune stimulation representing an approach that is highly
differentiated from antibody-based platforms,” said Phil Rowlands,
Ph.D., Head, Oncology Therapeutic Area Unit, Takeda. “It is a great
example of our commitment to collaborating with world-class partners to
pursue novel immuno-oncology targets and next-generation platforms, that
may one day deliver transformational medicines to patients.”
About Shattuck Labs, Inc.
Shattuck is a clinical-stage
biopharmaceutical company developing its Agonist Redirected Checkpoint
(ARC™) platform, a novel class of biologic medicines capable of
multifunctional activity with potential applications in oncology and
inflammatory diseases. Using its proprietary ARC™ platform, Shattuck is
building a pipeline of therapeutics, initially focused on the treatment
of solid tumors and hematologic malignancies. Shattuck has offices in
Austin, Texas and Durham, North Carolina. For more information, please
visit: http://www.shattucklabs.com.
Contacts
Andrew R. Neill
VP, Corporate Development and Strategy
Shattuck
Labs, Inc.
shattuckmedia@shattucklabs.com